Clinical Trials List
2025-01-21 - 2030-12-31
Phase I/II
Recruiting3
ICD-10C69.40
Malignant neoplasm of unspecified ciliary body
ICD-10C69.41
Malignant neoplasm of right ciliary body
ICD-10C69.42
Malignant neoplasm of left ciliary body
ICD-10Z51.12
Encounter for antineoplastic immunotherapy
ICD-9190.0
Malignant neoplasm of eyeball, except conjunctiva, cornea, retina and choroid
-
Trial Applicant
Merck Sharp & Dohme (I.A.) LLC
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/06/01
Investigators and Locations
Co-Principal Investigator
- 楊明翰 Division of Hematology & Oncology
- Hsiang-Fong Kao Division of Hematology & Oncology
- Ta-Ching Chen Division of Ophthalmology
- HUAI-CHENG HUANG Division of Hematology & Oncology
- FU-JEN HSUEH Division of Hematology & Oncology
- Yu-Chieh Tsai Division of Hematology & Oncology
- 莊建淮 Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Wei-Pang Chung Division of Hematology & Oncology
- 鍾秉軒 Division of Hematology & Oncology
- Shang-Yin Wu Division of Hematology & Oncology
- Yuh-Shyan Tsai Division of Urology
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
24 participants
-
Global
180 participants
